Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

爱斯万 - NMPA Drug Approval Details

Approvals/NMPA/Tegafur Gimeracil Oteracil Potassium Capsule

Approved

化学药品

Tegafur Gimeracil Oteracil Potassium Capsule

TAIHO PHARMACEUTICAL CO., LTD.🇨🇳 National Medical Products Administration

Approval Date: Aug 24, 2023
Approval ID: 8VIaC9vE8wt
Company: TAIHO PHARMACEUTICAL CO., LTD.
Type: 化学药品

Approval Details

Approval Id: 8VIaC9vE8wt
Approval Number: 国药准字HJ20130816
Generic Name: 替吉奥胶囊
Generic Name En: Tegafur Gimeracil Oteracil Potassium Capsule
Trade Name: 爱斯万
Drug Type: 化学药品
Dosage Form: 胶囊剂
Strength: 20mg
Reg Date: 2023-08-24
Expired Date: 2028-08-23
Company Name: TAIHO PHARMACEUTICAL CO., LTD.
Company Detail Path: /organization/taiho-pharmaceutical-co-ltd

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Aug 24, 2023

Approval ID

8VIaC9vE8wt

Type

化学药品

Back to NMPA Approvals